Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill

Mitchell S. Buckley, Kristen D. Knutson, Sumit K. Agarwal, Jake M. Lansburg, Laura M. Wicks, Rajeev C. Saggar, Emily C. Richards, Brian J. Kopp, Brian L. Erstad

Research output: Contribution to journalArticle

Abstract

Background:Optimal albumin use in the intensive care unit (ICU) remains challenging with inappropriate use approaching 50%. No published reports have described clinical pharmacist impact aimed at mitigating inappropriate albumin use in the ICU. Objective: To evaluate the clinical and economic impact of a clinical pharmacist–led intervention strategy targeting inappropriate albumin in the ICU. Methods: A retrospective cohort study evaluated all adult (≥18 years) ICU patients administered albumin at an academic medical center over a 2-year period. Institutional guidelines were developed with clinical pharmacists targeting inappropriate albumin use. The primary end point was to compare inappropriate use of albumin administered before and after pharmacist intervention implementation. Secondary analyses compared the overall albumin use between study periods. In-hospital mortality, length of stay, and albumin-related costs between study periods were also compared. Results: A total of 4419 patients were identified, with 2448 (55.4%) critically ill patients included. The pharmacist-led strategy resulted in a 50.9% reduction of inappropriate albumin use (P < 0.001). The rate of inappropriate albumin use was 44.3 ± 10.5 and 5.5 ± 2.9 g per patient-day in the preimplementation and postimplementation periods, respectively (P < 0.001). Costs associated with overall and inappropriate albumin use in the ICU decreased by 34.8% and 87.1%, respectively. Total annual cost-savings was $355 393 in the ICUs. No differences in clinical outcomes were found. Conclusion and Relevance: Clinical pharmacist–led interventions reduced overall and inappropriate albumin use and costs without negatively affecting clinical outcomes.

Original languageEnglish (US)
JournalAnnals of Pharmacotherapy
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Critical Illness
Albumins
Costs and Cost Analysis
Intensive Care Units
Pharmacists
Cost Savings
Hospital Mortality
Length of Stay
Cohort Studies
Retrospective Studies
Economics
Guidelines

Keywords

  • albumin
  • clinical pharmacist
  • critical care
  • intensive care unit

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Buckley, M. S., Knutson, K. D., Agarwal, S. K., Lansburg, J. M., Wicks, L. M., Saggar, R. C., ... Erstad, B. L. (Accepted/In press). Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028019877471

Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill. / Buckley, Mitchell S.; Knutson, Kristen D.; Agarwal, Sumit K.; Lansburg, Jake M.; Wicks, Laura M.; Saggar, Rajeev C.; Richards, Emily C.; Kopp, Brian J.; Erstad, Brian L.

In: Annals of Pharmacotherapy, 01.01.2019.

Research output: Contribution to journalArticle

Buckley, Mitchell S. ; Knutson, Kristen D. ; Agarwal, Sumit K. ; Lansburg, Jake M. ; Wicks, Laura M. ; Saggar, Rajeev C. ; Richards, Emily C. ; Kopp, Brian J. ; Erstad, Brian L. / Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill. In: Annals of Pharmacotherapy. 2019.
@article{b3641ffbdc134643ab6cf7d301540740,
title = "Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill",
abstract = "Background:Optimal albumin use in the intensive care unit (ICU) remains challenging with inappropriate use approaching 50{\%}. No published reports have described clinical pharmacist impact aimed at mitigating inappropriate albumin use in the ICU. Objective: To evaluate the clinical and economic impact of a clinical pharmacist–led intervention strategy targeting inappropriate albumin in the ICU. Methods: A retrospective cohort study evaluated all adult (≥18 years) ICU patients administered albumin at an academic medical center over a 2-year period. Institutional guidelines were developed with clinical pharmacists targeting inappropriate albumin use. The primary end point was to compare inappropriate use of albumin administered before and after pharmacist intervention implementation. Secondary analyses compared the overall albumin use between study periods. In-hospital mortality, length of stay, and albumin-related costs between study periods were also compared. Results: A total of 4419 patients were identified, with 2448 (55.4{\%}) critically ill patients included. The pharmacist-led strategy resulted in a 50.9{\%} reduction of inappropriate albumin use (P < 0.001). The rate of inappropriate albumin use was 44.3 ± 10.5 and 5.5 ± 2.9 g per patient-day in the preimplementation and postimplementation periods, respectively (P < 0.001). Costs associated with overall and inappropriate albumin use in the ICU decreased by 34.8{\%} and 87.1{\%}, respectively. Total annual cost-savings was $355 393 in the ICUs. No differences in clinical outcomes were found. Conclusion and Relevance: Clinical pharmacist–led interventions reduced overall and inappropriate albumin use and costs without negatively affecting clinical outcomes.",
keywords = "albumin, clinical pharmacist, critical care, intensive care unit",
author = "Buckley, {Mitchell S.} and Knutson, {Kristen D.} and Agarwal, {Sumit K.} and Lansburg, {Jake M.} and Wicks, {Laura M.} and Saggar, {Rajeev C.} and Richards, {Emily C.} and Kopp, {Brian J.} and Erstad, {Brian L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1060028019877471",
language = "English (US)",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",

}

TY - JOUR

T1 - Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill

AU - Buckley, Mitchell S.

AU - Knutson, Kristen D.

AU - Agarwal, Sumit K.

AU - Lansburg, Jake M.

AU - Wicks, Laura M.

AU - Saggar, Rajeev C.

AU - Richards, Emily C.

AU - Kopp, Brian J.

AU - Erstad, Brian L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background:Optimal albumin use in the intensive care unit (ICU) remains challenging with inappropriate use approaching 50%. No published reports have described clinical pharmacist impact aimed at mitigating inappropriate albumin use in the ICU. Objective: To evaluate the clinical and economic impact of a clinical pharmacist–led intervention strategy targeting inappropriate albumin in the ICU. Methods: A retrospective cohort study evaluated all adult (≥18 years) ICU patients administered albumin at an academic medical center over a 2-year period. Institutional guidelines were developed with clinical pharmacists targeting inappropriate albumin use. The primary end point was to compare inappropriate use of albumin administered before and after pharmacist intervention implementation. Secondary analyses compared the overall albumin use between study periods. In-hospital mortality, length of stay, and albumin-related costs between study periods were also compared. Results: A total of 4419 patients were identified, with 2448 (55.4%) critically ill patients included. The pharmacist-led strategy resulted in a 50.9% reduction of inappropriate albumin use (P < 0.001). The rate of inappropriate albumin use was 44.3 ± 10.5 and 5.5 ± 2.9 g per patient-day in the preimplementation and postimplementation periods, respectively (P < 0.001). Costs associated with overall and inappropriate albumin use in the ICU decreased by 34.8% and 87.1%, respectively. Total annual cost-savings was $355 393 in the ICUs. No differences in clinical outcomes were found. Conclusion and Relevance: Clinical pharmacist–led interventions reduced overall and inappropriate albumin use and costs without negatively affecting clinical outcomes.

AB - Background:Optimal albumin use in the intensive care unit (ICU) remains challenging with inappropriate use approaching 50%. No published reports have described clinical pharmacist impact aimed at mitigating inappropriate albumin use in the ICU. Objective: To evaluate the clinical and economic impact of a clinical pharmacist–led intervention strategy targeting inappropriate albumin in the ICU. Methods: A retrospective cohort study evaluated all adult (≥18 years) ICU patients administered albumin at an academic medical center over a 2-year period. Institutional guidelines were developed with clinical pharmacists targeting inappropriate albumin use. The primary end point was to compare inappropriate use of albumin administered before and after pharmacist intervention implementation. Secondary analyses compared the overall albumin use between study periods. In-hospital mortality, length of stay, and albumin-related costs between study periods were also compared. Results: A total of 4419 patients were identified, with 2448 (55.4%) critically ill patients included. The pharmacist-led strategy resulted in a 50.9% reduction of inappropriate albumin use (P < 0.001). The rate of inappropriate albumin use was 44.3 ± 10.5 and 5.5 ± 2.9 g per patient-day in the preimplementation and postimplementation periods, respectively (P < 0.001). Costs associated with overall and inappropriate albumin use in the ICU decreased by 34.8% and 87.1%, respectively. Total annual cost-savings was $355 393 in the ICUs. No differences in clinical outcomes were found. Conclusion and Relevance: Clinical pharmacist–led interventions reduced overall and inappropriate albumin use and costs without negatively affecting clinical outcomes.

KW - albumin

KW - clinical pharmacist

KW - critical care

KW - intensive care unit

UR - http://www.scopus.com/inward/record.url?scp=85075582182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075582182&partnerID=8YFLogxK

U2 - 10.1177/1060028019877471

DO - 10.1177/1060028019877471

M3 - Article

C2 - 31544470

AN - SCOPUS:85075582182

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

ER -